Document is current

Article History

Received: 25 March 2019

Accepted: 27 June 2019

First Online: 18 July 2019

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: Professor Hay receives/has received sessional fees and lecture fees from the Australian Medical Council, Therapeutic Guidelines publication, and New South Wales Institute of Psychiatry and royalties/honoraria from Hogrefe and Huber, McGraw Hill Education, and Blackwell Scientific Publications, Biomed Central and PlosMedicine and she has received research grants from the NHMRC and ARC. She is Chair of the National Eating Disorders Collaboration Steering Committee in Australia (2019-) and Member of the ICD-11 Working Group for Eating Disorders (2012-) and was Chair Clinical Practice Guidelines Project Working Group (Eating Disorders) of RANZCP (2012–2015). She has prepared a report under contract and conducted education for Psychiatrists funded by Shire Pharmaceuticals (2017–2018). All views in this paper are her own. Stephen Touyz has received royalties/honoraria from Hogrefe and Huber, McGraw Hill Education, and Blackwell Scientific Publications, and Biomed Central and he has received research grants from the NHMRC and ARC. He is consultant to Shire Pharmaceuticals. All views in this paper are his own. Ann Goebel-Fabbri is author of a book cited in this Editorial and receives royalties from Routledge Press. Paul Copeland served on an Advisory Board for AstraZenica.